利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

122 条记录 (耗时 0.036 秒)

    ECG-Based Cardiovascular Disease Detection Systems and Related Methods
    72.
    发明申请
    ECG-Based Cardiovascular Disease Detection Systems and Related Methods 有权

    公开(公告)号：US20220384044A1

    公开(公告)日：2022-12-01

    申请号：US17829351

    申请日：2022-05-31

    申请人： Tempus Labs, Inc. ,  Geisinger Clinic

    发明人： Alvaro E. Ulloa-Cerna ,  Noah Zimmerman ,  Greg Lee ,  Christopher M. Haggerty ,  Brandon K. Fomwalt ,  Ruijun Chen ,  John Pfeifer ,  Chris Good

    IPC分类号： G16H50/30 ,  A61B5/00 ,  A61B5/28

    摘要： A method for determining cardiology disease risk from electrocardiogram trace data and clinical data includes receiving electrocardiogram trace data associated with a patient, receiving the patient's clinical data, providing both sets of data to a trained machine learning composite model that is trained to evaluate the data with respect to each disease of a set of cardiology diseases including three or more of cardiac amyloidosis, aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, tricuspid regurgitation, abnormal reduced ejection fraction, or abnormal interventricular septal thickness, generating, by the model and based on the evaluation, a composite risk score reflecting a likelihood of the patient being diagnosed with one or more of the cardiology diseases within a predetermined period of time from when the electrocardiogram trace data was generated, and outputting the composite risk score to at least one of a memory or a display.

    MOLECULAR RESPONSE AND PROGRESSION DETECTION FROM CIRCULATING CELL FREE DNA
    73.
    发明申请
    MOLECULAR RESPONSE AND PROGRESSION DETECTION FROM CIRCULATING CELL FREE DNA 有权

    公开(公告)号：US20220367010A1

    公开(公告)日：2022-11-17

    申请号：US17859599

    申请日：2022-07-07

    申请人： Tempus Labs, Inc.

    发明人： Justin David Finkle ,  Christine Lo ,  Jonathan Alexander Heiss ,  Robert Tell ,  Sun Hae Hong

    IPC分类号： G16B40/00 ,  G16B20/20 ,  G16B5/20 ,  G06F30/27

    摘要： Methods, systems, and software are provided for monitoring a cancer condition of a test subject. The method includes obtaining a liquid biopsy sample from the subject at a second time point, occurring after a first time point, containing cell-free DNA fragments. Low-pass whole genome methylation sequencing of the cell-free DNA fragments is performed to obtain nucleic acid sequences having a methylation pattern for a corresponding cell-free DNA fragment. The nucleic acid sequences are mapped to a location on a reference genome. Methylation metrics are determined based on the methylation patterns and mapped locations of the nucleic acid sequences. A circulating tumor fraction is estimated from the methylation metrics, and the estimate is compared to an estimate of the circulating tumor fraction for the test subject at the first time point.

    Systems and Methods for Interrogating Clinical Documents for Characteristic Data
    74.
    发明申请
    Systems and Methods for Interrogating Clinical Documents for Characteristic Data 有权

    公开(公告)号：US20220319652A1

    公开(公告)日：2022-10-06

    申请号：US17837025

    申请日：2022-06-10

    申请人： Tempus Labs, Inc.

    发明人： Jonathan Ozeran

    IPC分类号： G16H10/60 ,  G16H50/20 ,  G06Q50/22 ,  G06F40/186

    摘要： A computer program product includes multiple microservices for interrogating clinical records according to one or more projects associated with patient datasets obtained from electronic copies of source documents from the clinical records. A first microservice generates a user interface including a first portion displaying source documents and, concurrently, a second portion displaying structured patient data fields organized into categories for entering structured patient data derived from the source documents displayed in the first portion. Categories and their organization are defined by a template and include cancer diagnosis, staging, tumor size, genetic results, and date of recurrence. A second microservice validates abstracted patient data according to validation rules applied to the categories, validation rules being assigned to the projects and performed on the categories as they are populated. A third microservice provides abstraction review performed by an assigned abstractor or an abstraction manager and spans one or more of the projects.

    ARTIFICIAL INTELLIGENCE ENGINE FOR DIRECTED HYPOTHESIS GENERATION AND RANKING
    75.
    发明申请
    ARTIFICIAL INTELLIGENCE ENGINE FOR DIRECTED HYPOTHESIS GENERATION AND RANKING 有权

    公开(公告)号：US20220261668A1

    公开(公告)日：2022-08-18

    申请号：US17651002

    申请日：2022-02-14

    申请人： Tempus Labs, Inc.

    发明人： Martin Stumpe ,  Alena Harley

    IPC分类号： G06N5/04 ,  G06F16/28 ,  G06F16/2457

    摘要： An artificial intelligence engine for directed hypothesis generation and ranking uses multiple heterogeneous knowledge graphs integrating disease-specific multi-omic data specific to a patient or cohort of patients. The engine also uses a knowledge graph representation of ‘what the world knows’ in the relevant bio-medical subspace. The engine applies a hypothesis generation module, a semantic search analysis component to allow fast acquiring and construction of cohorts, as well as aggregating, summarizing, visualizing and returning ranked multi-omic alterations in terms of clinical actionability and degree of surprise for individual samples and cohorts. The engine also applies a moderator module that ranks and filters hypotheses, where the most promising hypothesis can be presented to domain experts (e.g., physicians, oncologists, pathologists, radiologists and researchers) for feedback. The engine also uses a continuous integration module that iteratively refines and updates entities and relationships and their representations to yield higher quality of hypothesis generation over time.

    Unsupervised learning and prediction of lines of therapy from high-dimensional longitudinal medications data
    80.
    发明授权
    Unsupervised learning and prediction of lines of therapy from high-dimensional longitudinal medications data 有权

    公开(公告)号：US11295841B2

    公开(公告)日：2022-04-05

    申请号：US17001673

    申请日：2020-08-24

    申请人： Tempus Labs, Inc.

    发明人： Mathew Barber ,  Ryan Mork

    IPC分类号： G16H20/10 ,  G16H10/60 ,  G06N20/00 ,  G06K9/00 ,  G16H50/30

    摘要： In one aspect, the present disclosure provides a method for labeling one or more medications concurrently administered to a patient as a line of therapy. The method includes identifying medical records of the patient from a plurality of digital records, creating, from the subset of medical records, a plurality of treatment intervals including at least one medication administered to the patient and a time interval, associating medications of the one or more treatments with a respective treatment interval when the administration of the medication falls within the time interval, refining the time interval of a respective treatment interval when a treatment of the one or more treatments falls outside the time interval but within an extension period, identifying one or more potential lines of therapy from the plurality of treatment intervals, and labeling the potential line of therapy having the highest maximum likelihood estimation as the line of therapy.